Japan Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Japan Breast Cancer Therapeutics Market Analysis

$ 3999

The Japan breast cancer therapeutics market is expected to witness growth from $1.13 Bn in 2022 with a CAGR of 13.4% for the forecasted year 2022-2030 to $3.09 Bn in 2030 due to growth drivers like the increasing incidence of breast cancer and awareness programs in Japan. The breast cancer therapeutics market is segmented by therapy, by cancer type, and by distribution channel. Major players in Japan breast cancer therapeutics market include Takeda Pharmaceutical Co. Ltd., Eisai Co., Ltd, AstraZeneca PLC.

ID: IN10JPPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan

Buy Now

Japan Breast Cancer Therapeutics Market Executive Analysis

The Japan Breast Cancer Therapeutics market size is at around $1.13 Bn in 2022 and is projected to reach $3.09 Bn in 2030, exhibiting a CAGR of 13.4% during the forecast period. Healthcare costs estimated to have been paid to medical facilities in fiscal 2021 increased to a record $340 Mn, up $160 Mn (or 4.6%) from the year before. The cost of hospitalization climbed by 2.8% to $140 Mn, while the cost of outpatient services, home visits, and other non-hospitalized medical care increased by 7.5% to $120 Mn. Prescription drug and dental treatment costs increased by 2.7% and 4.8%, respectively, during this time.

Japan has lower rates of morbidity and mortality from breast cancer than Western nations. In Japan, the 10-year survival rate following breast-conserving therapy is 85%-95%, compared to about 60%-80% in Western nations. In patients with breast cancer, the prognosis is predicted by the disease stage and other clinical variables at diagnosis. The progesterone receptor (PgR) and the oestrogen receptor (ER), two hormone receptors, have garnered more attention recently in relation to breast cancer therapy approaches and prognostic evaluation.

Japan Breast Cancer Therapeutics Market

Market Dynamics

Market Growth Drivers

The market is primarily driven by the increasing incidence of breast cancer and awareness campaigns run by public and private organisations. The Japan Cancer Society created the "Pink Ribbon Festival" to educate the public on the value of early breast cancer detection, diagnosis, and treatment. The breast cancer charity in Japan, known as Run for the Cure, promotes breast cancer awareness and education.

Market Restraints

The expansion of the Japanese breast cancer therapeutics market is anticipated to be hampered by the high costs of breast cancer therapies, the rising expenses of early and late-stage disease therapy, and the adverse effects of breast cancer medications. Additionally, Japan's rigid regulatory rules restrain market expansion.

Competitive Landscape

Key Players

Taiho Pharmaceutical (JPN)
Daiichi Sankyo (JPN)
Takeda Pharmaceutical Co. Ltd. (JPN)
Eisai Co., Ltd (JPN)
AstraZeneca PLC
Bayer AG
GlaxoSmithKline PLC
Mylan NV
Novartis International AG

Healthcare Policies and Regulatory Landscape

Japanese public health insurance now includes coverage for mastectomies and oophorectomies for patients with breast cancer who face the risk of developing new cancers due to a genetic mutation. Cancer patients with hereditary breast cancer syndrome diagnoses are eligible for insurance coverage. Additionally, the Japanese government has recognized a number of institutions as breast cancer treatment facilities where patients can get specialized care from breast cancer experts. The government also provides reimbursement for expensive treatments such as targeted therapy and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.